Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of ...

In the analyses, 68% percent of patients received prior CHOP-based therapy, 35% had salvage chemotherapy, 20% had autologous stem cell transplant, 17% had an HDAC inhibitor, and 38% had prior exposure ...

Beam Therapeutics (BEAM) announced new safety and efficacy data from its BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel, formerly ...

The safety profile remained consistent with busulfan conditioning, autologous hematopoietic stem cell transplantation, and underlying SCD. The most common treatment-emergent adverse events included ...

Beam Therapeutics Inc. (NASDAQ:BEAM) saw its shares rise 1.7% in premarket trading Monday after releasing updated results ...

Investors are more concerned over the next phase of the industry cycle and the impact it will have on Premier’s profit ...

Pierre Fabre Pharmaceuticals Inc., today announced updated results presented at the 67th American Society of Hematology (ASH) ...

Biomarker-activated cancer drug-candidate LP-184 demonstrates encouraging efficacy signals in DNA damage repair deficient ...

Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...

Odronextamab combined with CHOP showed high efficacy in untreated DLBCL, with a 100% response rate at the 160 mg dose. The safety profile was manageable, with no new safety signals, and most patients ...

Prospective-trial analysis published in the Journal of the National Cancer Institute predicts residual cancer burden from ...

Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimensAccelerated step-up dosing and higher dosing ...